BioSpace News Archive

ReWalk Robotics Ltd. announced that it will host a conference call and webcast on Tuesday, July 11, 2023 to discuss the recent proposal from the Centers for Medicare & Medicaid Services (“CMS”) to include personal exoskeletons in the Medicare benefit category for braces as part of the Calendar Year 2024 Home Health Prospective Payment System Proposed Rule, CMS-1780-P (“Proposed Rule”), released on June 30, 2023.

Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) is pleased to announce that it has been granted final approval for its double blind, placebo controlled Phase II Clinical Trial for the treatment of Autism Spectrum Disorder (ASD) from the Israel Ministry of Health.

The Preeclampsia Foundation is seeking Letters of Intent for the Peter Joseph Pappas Research Grants funding program, designed to accelerate preeclampsia research.

Infinity Pharmaceuticals, Inc. announced today that leading independent proxy advisor Institutional Shareholder Services Inc. (“ISS”) has recommended that Infinity stockholders vote FOR the merger with MEI Pharma, Inc.

Palisade Bio, Inc. today announced the completion of patient enrollment in its dose optimization study of LB1148.

apoQlar, a pioneering healthtech company, has successfully secured a funding round led by venture capital firm YZR Capital, specializing in health tech investments.

Evotec SE announced that the U.S. Department of Defense has awarded Evotec’s Seattle-based subsidiary, Just - Evotec Biologics, Inc. a contract valued up to $ 74 m for the rapid development of monoclonal antibody -based drug product prototypes targeting orthopoxviruses.

Insulet Corporation announced plans to release its financial results for the second quarter of 2023 on August 8, 2023 after the close of the financial markets.

KalVista Pharmaceuticals, Inc., announced that the compensation committee of KalVista’s board of directors granted two newly-hired employees inducement options to purchase an aggregate of 13,000 shares of KalVista common stock on July 3, 2023 as inducements material to each employee entering into employment with KalVista.

Olema Pharmaceuticals, Inc. today announced that the Company granted stock options to three new employees to purchase an aggregate of 32,300 shares of the Company’s common stock, effective as of July 3, 2023.